help button home button Endocrine Society JCEM JCEM Call for Nominations for EIC
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow A correction has been published
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rapuri, P. B.
Right arrow Articles by Haynatzki, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rapuri, P. B.
Right arrow Articles by Haynatzki, G.
The Journal of Clinical Endocrinology & Metabolism Vol. 89, No. 10 4954-4962
Copyright © 2004 by The Endocrine Society

Endogenous Levels of Serum Estradiol and Sex Hormone Binding Globulin Determine Bone Mineral Density, Bone Remodeling, the Rate of Bone Loss, and Response to Treatment with Estrogen in Elderly Women

Prema B. Rapuri, J. Christopher Gallagher and Gleb Haynatzki

Bone Metabolism Unit (P.B.R., J.C.G.) and Osteoporosis Research Center (G.H.), Creighton University School of Medicine, Omaha, Nebraska 68131

Address all correspondence and requests for reprints to: Prema Rapuri, Bone Metabolism Unit, Creighton University, School of Medicine, 601 North 30th Street, Room 6718, Omaha, Nebraska 68131. E-mail: thiyyari{at}creighton.edu.

A total of 489 elderly women aged 65–75 yr who participated in a 3-yr, randomized, blinded osteoporosis trial underwent measurements of serum estradiol, bioavailable estradiol, and SHBG. At baseline, bone mineral density (BMD) was lower at the femoral sites (7–19%, P < 0.05), total body (6–8%, P < 0.05), and spine (5–9%, P = 0.2) in women in the lowest tertile for serum total estradiol [<9 pg/ml (33 pmol/liter)], serum bioavailable estradiol [<2.4 pg/ml (8.8 pmol/liter)], or highest tertile for serum SHBG (>165 nmol/liter), compared with women in the highest tertiles of total estradiol [>13.3 pg/ml (49 pmol/liter)] and bioavailable estradiol [>4 pg/ml (14 pmol/liter)] or lowest tertile for SHBG (<113 nmol/liter). Bone markers were increased in women in the lowest tertile for serum total estradiol (not significant) and bioavailable estradiol (P < 0.05) and highest tertile for SHBG (P < 0.05).

In the longitudinal study, the rate of bone loss in the placebo group was significantly higher in total body (P < 0.05) and spine (P < 0.05) in women in the lowest tertile, compared with the highest tertile of serum bioavailable estradiol.

After treatment with conjugated equine estrogens 0.625 mg/d, the increase in BMD was 4–6% higher at the femoral sites (P < 0.05), total body (P < 0.05), and spine (not significant), in the lowest tertile, compared with the highest tertile of serum bioavailable estradiol or highest tertile, compared with the lowest tertile of serum SHBG.

In summary, small variations in endogenous serum estradiol and high serum SHBG determine differences in BMD and rate of bone loss in elderly women and also affect the response to treatment with estrogen. Women with a serum estradiol level of less than 9 pg/ml (33 pmol/liter) are optimal candidates for estrogen therapy for osteoporosis prevention.




This article has been cited by other articles:


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
F. Z. Stanczyk, J. S. Lee, and R. J. Santen
Standardization of Steroid Hormone Assays: Why, How, and When?
Cancer Epidemiol. Biomarkers Prev., September 1, 2007; 16(9): 1713 - 1719.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
J. A. Riancho, C. Valero, A. Naranjo, D. J. Morales, C. Sanudo, and M. T. Zarrabeitia
Identification of an Aromatase Haplotype That Is Associated with Gene Expression and Postmenopausal Osteoporosis
J. Clin. Endocrinol. Metab., February 1, 2007; 92(2): 660 - 665.
[Abstract] [Full Text] [PDF]


Home page
Eur J EndocrinolHome page
M. T Zarrabeitia, J. L Hernandez, C. Valero, A. Zarrabeitia, J. A Amado, J. Gonzalez-Macias, and J. A Riancho
Adiposity, estradiol, and genetic variants of steroid-metabolizing enzymes as determinants of bone mineral density
Eur. J. Endocrinol., January 1, 2007; 156(1): 117 - 122.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
S. A. Missmer, D. Spiegelman, E. R. Bertone-Johnson, R. L. Barbieri, M. N. Pollak, and S. E. Hankinson
Reproducibility of Plasma Steroid Hormones, Prolactin, and Insulin-like Growth Factor Levels among Premenopausal Women over a 2- to 3-Year Period.
Cancer Epidemiol. Biomarkers Prev., May 1, 2006; 15(5): 972 - 978.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2004 by The Endocrine Society